Insider Buying: Vivani Medical (NASDAQ:VANI) Director Buys $1,999,999.26 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams purchased 1,587,301 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the transaction, the director directly owned 34,531,785 shares of the company’s stock, valued at $43,510,049.10. This represents a 4.82% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Gregg Williams also recently made the following trade(s):

• On Wednesday, April 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The shares were purchased at an average price of $1.26 per share, with a total value of $1,999,999.26.
• On Sunday, March 15th, Gregg Williams purchased 1,575,231 shares of Vivani Medical stock. The shares were purchased at an average price of $1.07 per share, with a total value of $1,685,497.17.

Vivani Medical Stock Performance

Shares of VANI opened at $1.16 on Friday. Vivani Medical, Inc. has a one year low of $0.92 and a one year high of $1.92. The stock has a market capitalization of $100.04 million, a price-to-earnings ratio of -2.90 and a beta of 2.35. The stock has a 50 day moving average price of $1.18 and a 200 day moving average price of $1.28.

Vivani Medical (NASDAQ:VANI) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). On average, analysts predict that Vivani Medical, Inc. will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. State Street Corp raised its holdings in shares of Vivani Medical by 12.5% during the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after acquiring an additional 16,070 shares during the period. Susquehanna International Group LLP raised its holdings in shares of Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after acquiring an additional 16,200 shares during the period. Citadel Advisors LLC purchased a new position in shares of Vivani Medical during the 3rd quarter worth $26,000. Jane Street Group LLC purchased a new position in shares of Vivani Medical during the 4th quarter worth $60,000. Finally, Renaissance Technologies LLC grew its stake in shares of Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after buying an additional 53,127 shares during the period. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price target on shares of Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.50.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.